These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 30779113)
1. Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages. Maeda A; Digifico E; Andon FT; Mantovani A; Allavena P Eur J Immunol; 2019 May; 49(5):801-811. PubMed ID: 30779113 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246 [TBL] [Abstract][Full Text] [Related]
3. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy. Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787 [TBL] [Abstract][Full Text] [Related]
4. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569 [TBL] [Abstract][Full Text] [Related]
5. Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands. Klein JC; Wild CA; Lang S; Brandau S Cancer Immunol Immunother; 2016 Jun; 65(6):689-700. PubMed ID: 27034235 [TBL] [Abstract][Full Text] [Related]
6. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Goswami KK; Ghosh T; Ghosh S; Sarkar M; Bose A; Baral R Cell Immunol; 2017 Jun; 316():1-10. PubMed ID: 28433198 [TBL] [Abstract][Full Text] [Related]
7. Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors. Dacoba TG; Anfray C; Mainini F; Allavena P; Alonso MJ; Torres Andón F; Crecente-Campo J Front Immunol; 2020; 11():1412. PubMed ID: 32733469 [No Abstract] [Full Text] [Related]
8. The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline ε transcription through the induction of BCL6 expression in B cells. Yoon HK; Shim YS; Kim PH; Park SR Cell Immunol; 2019 Apr; 338():1-8. PubMed ID: 30850088 [TBL] [Abstract][Full Text] [Related]
9. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Zheng X; Turkowski K; Mora J; Brüne B; Seeger W; Weigert A; Savai R Oncotarget; 2017 Jul; 8(29):48436-48452. PubMed ID: 28467800 [TBL] [Abstract][Full Text] [Related]
10. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages. Ye J; Yang Y; Dong W; Gao Y; Meng Y; Wang H; Li L; Jin J; Ji M; Xia X; Chen X; Jin Y; Liu Y Int J Nanomedicine; 2019; 14():3203-3220. PubMed ID: 31118632 [No Abstract] [Full Text] [Related]
11. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma. Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167 [TBL] [Abstract][Full Text] [Related]
12. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment. Cassano JM; Schnabel LV; Goodale MB; Fortier LA Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127 [TBL] [Abstract][Full Text] [Related]
13. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles. Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235 [TBL] [Abstract][Full Text] [Related]
14. The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists. Johnson RH; Kho DT; O' Carroll SJ; Angel CE; Graham ES Sci Rep; 2018 Jul; 8(1):10102. PubMed ID: 29973684 [TBL] [Abstract][Full Text] [Related]
15. Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting. Fiani ML; Barreca V; Sargiacomo M; Ferrantelli F; Manfredi F; Federico M Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878276 [TBL] [Abstract][Full Text] [Related]
16. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260 [TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Wang Y; Lin YX; Qiao SL; An HW; Ma Y; Qiao ZY; Rajapaksha RP; Wang H Biomaterials; 2017 Jan; 112():153-163. PubMed ID: 27768970 [TBL] [Abstract][Full Text] [Related]
18. Diverse macrophages polarization in tumor microenvironment. Rhee I Arch Pharm Res; 2016 Nov; 39(11):1588-1596. PubMed ID: 27562774 [TBL] [Abstract][Full Text] [Related]
19. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Jiang C; Yuan F; Wang J; Wu L Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495 [TBL] [Abstract][Full Text] [Related]
20. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]